Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone Add-on to Metformin and Empagliflozin in T2DM
NCT03627182Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lobeglitazone in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03627182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627182.